18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

Michinori Ezura; Akio Kikuchi; Nobuyuki Okamura; Aiko Ishiki; Takafumi Hasegawa; Ryuichi Harada; Shoichi Watanuki; Yoshihito Funaki; Kotaro Hiraoka; Toru Baba; Naoto Sugeno; Shun Yoshida; Junpei Kobayashi; Michiko Kobayashi; Ohito Tano; Shun Ishiyama; Takaaki Nakamura; Ichiro Nakashima; Shunji Mugikura; Ren Iwata; Yasuyuki Taki; Katsutoshi Furukawa; Hiroyuki Arai; Shozo Furumoto; Manabu Tashiro; Kazuhiko Yanai; Yukitsuka Kudo; Atsushi Takeda; Masashi Aoki

doi:10.3389/fnagi.2021.761010

¹⁸F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

Michinori Ezura, Akio Kikuchi, Nobuyuki Okamura, Aiko Ishiki, Takafumi Hasegawa, Ryuichi Harada, Shoichi Watanuki, Yoshihito Funaki, Kotaro Hiraoka, Toru Baba, Naoto Sugeno, Shun Yoshida, Junpei Kobayashi, Michiko Kobayashi, Ohito Tano, Shun Ishiyama, Takaaki Nakamura, Ichiro Nakashima, Shunji Mugikura, Ren IwataYasuyuki Taki, Katsutoshi Furukawa, Hiroyuki Arai, Shozo Furumoto, Manabu Tashiro, Kazuhiko Yanai, Yukitsuka Kudo, Atsushi Takeda, Masashi Aoki

研究成果: Article › 査読

5 被引用数 (Scopus)

抄録

Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using ¹⁸F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer’s disease (AD) and whether ¹⁸F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: ¹⁸F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke’s Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson’s Disease Rating Scale Motor Score, and PSP Rating Scale. Results: ¹⁸F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. ¹⁸F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, ¹⁸F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional ¹⁸F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using ¹⁸F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.

本文言語	English
論文番号	761010
ジャーナル	Frontiers in Aging Neuroscience
巻	13
DOI	https://doi.org/10.3389/fnagi.2021.761010
出版ステータス	Published - 2021 11月 29

ASJC Scopus subject areas

加齢科学
認知神経科学

文献へのアクセス

10.3389/fnagi.2021.761010

他のファイルとリンク

引用スタイル

Ezura, M., Kikuchi, A., Okamura, N., Ishiki, A., Hasegawa, T., Harada, R., Watanuki, S., Funaki, Y., Hiraoka, K., Baba, T., Sugeno, N., Yoshida, S., Kobayashi, J., Kobayashi, M., Tano, O., Ishiyama, S., Nakamura, T., Nakashima, I., Mugikura, S., ... Aoki, M. (2021). ¹⁸F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies. Frontiers in Aging Neuroscience, 13, [761010]. https://doi.org/10.3389/fnagi.2021.761010

Ezura, M, Kikuchi, A, Okamura, N, Ishiki, A, Hasegawa, T , Harada, R, Watanuki, S, Funaki, Y , Hiraoka, K, Baba, T, Sugeno, N, Yoshida, S, Kobayashi, J, Kobayashi, M, Tano, O, Ishiyama, S, Nakamura, T, Nakashima, I, Mugikura, S, Iwata, R, Taki, Y, Furukawa, K, Arai, H, Furumoto, S , Tashiro, M, Yanai, K, Kudo, Y, Takeda, A & Aoki, M 2021, '¹⁸F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies', Frontiers in Aging Neuroscience, vol. 13, 761010. https://doi.org/10.3389/fnagi.2021.761010

@article{b6a5a88f80984a2abeb6c587e339db7d,

title = "18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies",

abstract = "Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer{\textquoteright}s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: 18F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke{\textquoteright}s Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson{\textquoteright}s Disease Rating Scale Motor Score, and PSP Rating Scale. Results: 18F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. 18F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, 18F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional 18F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using 18F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.",

keywords = "Alzheimer{\textquoteright}s disease (AD), F-THK5351, corticobasal syndrome (CBS), monoamine oxidase B (MAO-B), positron emission tomography (PET), progressive supranuclear palsy (PSP), tau deposits, tauopathy",

author = "Michinori Ezura and Akio Kikuchi and Nobuyuki Okamura and Aiko Ishiki and Takafumi Hasegawa and Ryuichi Harada and Shoichi Watanuki and Yoshihito Funaki and Kotaro Hiraoka and Toru Baba and Naoto Sugeno and Shun Yoshida and Junpei Kobayashi and Michiko Kobayashi and Ohito Tano and Shun Ishiyama and Takaaki Nakamura and Ichiro Nakashima and Shunji Mugikura and Ren Iwata and Yasuyuki Taki and Katsutoshi Furukawa and Hiroyuki Arai and Shozo Furumoto and Manabu Tashiro and Kazuhiko Yanai and Yukitsuka Kudo and Atsushi Takeda and Masashi Aoki",

note = "Funding Information: in Progressive Supranuclear Palsy. Front. Aging. Neurosci. 9:440. doi: 10.3389/ fnagi.2017.00440 Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M. Y., et al. (2013). Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimers Dis. 34, 457–468. doi: 10.3233/JAD-122059 Coakeley, S., and Strafella, A. P. (2017). Imaging tau pathology in Parkinsonisms. NPJ Parkinsons Dis. 3:22. doi: 10.1038/s41531-017-0023-3 Dani, M., Brooks, D. J., and Edison, P. (2016). Tau imaging in neurodegenerative diseases. Eur. J. Nucl. Med. Mol. Imaging 43, 1139–1150. doi: 10.1007/s00259-015-3231-2 Day, G. S., Lim, T. S., Hassenstab, J., Goate, A. M., Grant, E. A., Roe, C. M., et al. (2017). Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 88, 1273–1281. doi: 10.1212/ WNL.0000000000003770 Ezura, M., Kikuchi, A., Ishiki, A., Okamura, N., Hasegawa, T., Harada, R., et al. (2019). Longitudinal changes in 18F-THK5351 positron emission tomography in corticobasal syndrome. Eur. J. Neurol. 26, 1205–1211. doi: 10.1111/ene.13966 Fujioka, S., Morishita, T., Takano, K., Takahashi, N., Kurihara, K., Nishida, A., et al. (2021). A novel diagnostic marker for progressive supranuclear palsy targeting atrophy of the subthalamic nucleus. J. Neurol. Sci. 423:117366. doi: 10.1016/j.jns.2021.117366 Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., et al. (2016). 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J. Nucl. Med. 57, 208–214. doi: 10.2967/ jnumed.115.164848 Harada, R., Ishiki, A., Kai, H., Sato, N., Furukawa, K., Furumoto, S., et al. (2018). Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease. J. Nucl. Med. 59, 671–674. doi: 10.2967/ jnumed.117.197426 Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., et al. (2017). Tau imaging with [18F]THK-5351 in progressive supranuclear palsy. Eur. J. Neurol. 24, 130–136. doi: 10.1111/ene.13164 Ishiki, A., Harada, R., Kai, H., Sato, N., Totsune, T., Tomita, N., et al. (2018). Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol. Commun. 6:53. doi: 10.1186/s40478-018-0556-7 Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., et al. (2016). Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110–119. doi: 10.1002/ana.24546 Kikuchi, A., Takeda, A., Okamura, N., Tashiro, M., Hasegawa, T., Furumoto, S., et al. (2010). In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 133, 1772–1778. doi: 10.1093/brain/awq091 Kikuchi, A., Okamura, N., Hasegawa, T., Harada, R., Watanuki, S., Funaki, Y., et al. (2016). In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 87, 2309–2316. doi: 10.1212/WNL. 0000000000003375 Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer{\textquoteright}s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306–319. doi: 10.1002/ana.20009 Leyns, C. E. G., and Holtzman, D. M. (2017). Glial contributions to neurodegeneration in tauopathies. Mol. Neurodegener. 12:50. doi: 10.1186/ s13024-017-0192-x Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., et al. (1996). Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47, 1–9. doi: 10.1212/WNL.47.1.1 Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., et al. (2003). Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467–486. doi: 10.1002/mds.10459 Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., et al. (2013). Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094–1108. doi: 10.1016/j. neuron.2013.07.037 Mathew, R., Bak, T. H., and Hodges, J. R. (2012). Diagnostic criteria for corticobasal syndrome: a comparative study. J. Neurol. Neurosurg. Psychiatry 83, 405–410. doi: 10.1136/jnnp-2011-300875 McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer{\textquoteright}s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer{\textquoteright}s Disease. Neurology 34, 939–944. doi: 10. 1212/wnl.34.7.939 Ng, K. P., Pascoal, T. A., Mathotaarachchi, S., Therriault, J., Kang, M. S., Shin, M., et al. (2017). Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res. Ther. 9:25. doi: 10.1186/s13195-017-0253-y Niethammer, M., Tang, C. C., Feigin, A., Allen, P. J., Heinen, L., Hellwig, S., et al. (2014). A disease-specific metabolic brain network associated with corticobasal degeneration. Brain 137, 3036–3046. doi: 10.1093/brain/aw u256 Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., and Kudo, Y. (2018). The development and validation of tau PET tracers: current status and future directions. Clin. Transl. Imaging 6, 305–316. doi: 10.1007/s40336-018-0290-y Osaki, Y., Ben-Shlomo, Y., Lees, A. J., Daniel, S. E., Colosimo, C., Wenning, G., et al. (2004). Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov. Disord. 19, 181–189. doi: 10.1002/mds. 10680 Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hagerstrom, D., et al. (2017a). Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy. Mov. Disord. 32, 108–114. doi: 10.1002/mds. 26813 Smith, R., Scholl, M., Widner, H., van Westen, D., Svenningsson, P., Hagerstrom, D., et al. (2017b). In vivo retention of 18F-AV-1451 in corticobasal syndrome. Neurology 89, 845–853. doi: 10.1212/WNL.000000000000 4264 Tago, T., Toyohara, J., Sengoku, R., Murayama, S., and Ishii, K. (2019). Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis: An Autopsy-Confirmed Case. Clin. Nucl. Med. 44, 507–509. doi: 10. 1097/RLU.0000000000002564 Tong, J., Meyer, J. H., Furukawa, Y., Boileau, I., Chang, L. J., Wilson, A. A., et al. (2013). Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J. Cereb. Blood Flow. Metab. 33, 863–871. doi: 10.1038/jcbfm.2013.19 Yoshida, M. (2014). Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 34, 555–570. doi: 10.1111/neup. 12143 Conflict of Interest: NO, SF, and YK declare that this study received funding from GE Healthcare, Clino Ltd. and Sumitomo Electric Industries. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Funding Information: This study was supported in part by Grants-in-Aid for Scientific Research (C) (23591266, 26461303, and 17K09789) and (B) (24390219 and 15H04900) and Grant-in-Aid for Scientific Research on Innovative Areas (Brain Protein Aging and Dementia Control) (26117003) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan and Novartis Research Grants. Publisher Copyright: Copyright {\textcopyright} 2021 Ezura, Kikuchi, Okamura, Ishiki, Hasegawa, Harada, Watanuki, Funaki, Hiraoka, Baba, Sugeno, Yoshida, Kobayashi, Kobayashi, Tano, Ishiyama, Nakamura, Nakashima, Mugikura, Iwata, Taki, Furukawa, Arai, Furumoto, Tashiro, Yanai, Kudo, Takeda and Aoki.",

year = "2021",

month = nov,

day = "29",

doi = "10.3389/fnagi.2021.761010",

language = "English",

volume = "13",

journal = "Frontiers in Aging Neuroscience",

issn = "1663-4365",

publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - 18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

AU - Ezura, Michinori

AU - Kikuchi, Akio

AU - Okamura, Nobuyuki

AU - Ishiki, Aiko

AU - Hasegawa, Takafumi

AU - Harada, Ryuichi

AU - Watanuki, Shoichi

AU - Funaki, Yoshihito

AU - Hiraoka, Kotaro

AU - Baba, Toru

AU - Sugeno, Naoto

AU - Yoshida, Shun

AU - Kobayashi, Junpei

AU - Kobayashi, Michiko

AU - Tano, Ohito

AU - Ishiyama, Shun

AU - Nakamura, Takaaki

AU - Nakashima, Ichiro

AU - Mugikura, Shunji

AU - Iwata, Ren

AU - Taki, Yasuyuki

AU - Furukawa, Katsutoshi

AU - Arai, Hiroyuki

AU - Furumoto, Shozo

AU - Tashiro, Manabu

AU - Yanai, Kazuhiko

AU - Kudo, Yukitsuka

AU - Takeda, Atsushi

AU - Aoki, Masashi

N1 - Funding Information: in Progressive Supranuclear Palsy. Front. Aging. Neurosci. 9:440. doi: 10.3389/ fnagi.2017.00440 Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M. Y., et al. (2013). Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimers Dis. 34, 457–468. doi: 10.3233/JAD-122059 Coakeley, S., and Strafella, A. P. (2017). Imaging tau pathology in Parkinsonisms. NPJ Parkinsons Dis. 3:22. doi: 10.1038/s41531-017-0023-3 Dani, M., Brooks, D. J., and Edison, P. (2016). Tau imaging in neurodegenerative diseases. Eur. J. Nucl. Med. Mol. Imaging 43, 1139–1150. doi: 10.1007/s00259-015-3231-2 Day, G. S., Lim, T. S., Hassenstab, J., Goate, A. M., Grant, E. A., Roe, C. M., et al. (2017). Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 88, 1273–1281. doi: 10.1212/ WNL.0000000000003770 Ezura, M., Kikuchi, A., Ishiki, A., Okamura, N., Hasegawa, T., Harada, R., et al. (2019). Longitudinal changes in 18F-THK5351 positron emission tomography in corticobasal syndrome. Eur. J. Neurol. 26, 1205–1211. doi: 10.1111/ene.13966 Fujioka, S., Morishita, T., Takano, K., Takahashi, N., Kurihara, K., Nishida, A., et al. (2021). A novel diagnostic marker for progressive supranuclear palsy targeting atrophy of the subthalamic nucleus. J. Neurol. Sci. 423:117366. doi: 10.1016/j.jns.2021.117366 Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., et al. (2016). 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J. Nucl. Med. 57, 208–214. doi: 10.2967/ jnumed.115.164848 Harada, R., Ishiki, A., Kai, H., Sato, N., Furukawa, K., Furumoto, S., et al. (2018). Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease. J. Nucl. Med. 59, 671–674. doi: 10.2967/ jnumed.117.197426 Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., et al. (2017). Tau imaging with [18F]THK-5351 in progressive supranuclear palsy. Eur. J. Neurol. 24, 130–136. doi: 10.1111/ene.13164 Ishiki, A., Harada, R., Kai, H., Sato, N., Totsune, T., Tomita, N., et al. (2018). Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol. Commun. 6:53. doi: 10.1186/s40478-018-0556-7 Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., et al. (2016). Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110–119. doi: 10.1002/ana.24546 Kikuchi, A., Takeda, A., Okamura, N., Tashiro, M., Hasegawa, T., Furumoto, S., et al. (2010). In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 133, 1772–1778. doi: 10.1093/brain/awq091 Kikuchi, A., Okamura, N., Hasegawa, T., Harada, R., Watanuki, S., Funaki, Y., et al. (2016). In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 87, 2309–2316. doi: 10.1212/WNL. 0000000000003375 Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306–319. doi: 10.1002/ana.20009 Leyns, C. E. G., and Holtzman, D. M. (2017). Glial contributions to neurodegeneration in tauopathies. Mol. Neurodegener. 12:50. doi: 10.1186/ s13024-017-0192-x Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., et al. (1996). Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47, 1–9. doi: 10.1212/WNL.47.1.1 Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., et al. (2003). Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467–486. doi: 10.1002/mds.10459 Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., et al. (2013). Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094–1108. doi: 10.1016/j. neuron.2013.07.037 Mathew, R., Bak, T. H., and Hodges, J. R. (2012). Diagnostic criteria for corticobasal syndrome: a comparative study. J. Neurol. Neurosurg. Psychiatry 83, 405–410. doi: 10.1136/jnnp-2011-300875 McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–944. doi: 10. 1212/wnl.34.7.939 Ng, K. P., Pascoal, T. A., Mathotaarachchi, S., Therriault, J., Kang, M. S., Shin, M., et al. (2017). Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res. Ther. 9:25. doi: 10.1186/s13195-017-0253-y Niethammer, M., Tang, C. C., Feigin, A., Allen, P. J., Heinen, L., Hellwig, S., et al. (2014). A disease-specific metabolic brain network associated with corticobasal degeneration. Brain 137, 3036–3046. doi: 10.1093/brain/aw u256 Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., and Kudo, Y. (2018). The development and validation of tau PET tracers: current status and future directions. Clin. Transl. Imaging 6, 305–316. doi: 10.1007/s40336-018-0290-y Osaki, Y., Ben-Shlomo, Y., Lees, A. J., Daniel, S. E., Colosimo, C., Wenning, G., et al. (2004). Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov. Disord. 19, 181–189. doi: 10.1002/mds. 10680 Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hagerstrom, D., et al. (2017a). Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy. Mov. Disord. 32, 108–114. doi: 10.1002/mds. 26813 Smith, R., Scholl, M., Widner, H., van Westen, D., Svenningsson, P., Hagerstrom, D., et al. (2017b). In vivo retention of 18F-AV-1451 in corticobasal syndrome. Neurology 89, 845–853. doi: 10.1212/WNL.000000000000 4264 Tago, T., Toyohara, J., Sengoku, R., Murayama, S., and Ishii, K. (2019). Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis: An Autopsy-Confirmed Case. Clin. Nucl. Med. 44, 507–509. doi: 10. 1097/RLU.0000000000002564 Tong, J., Meyer, J. H., Furukawa, Y., Boileau, I., Chang, L. J., Wilson, A. A., et al. (2013). Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J. Cereb. Blood Flow. Metab. 33, 863–871. doi: 10.1038/jcbfm.2013.19 Yoshida, M. (2014). Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 34, 555–570. doi: 10.1111/neup. 12143 Conflict of Interest: NO, SF, and YK declare that this study received funding from GE Healthcare, Clino Ltd. and Sumitomo Electric Industries. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Funding Information: This study was supported in part by Grants-in-Aid for Scientific Research (C) (23591266, 26461303, and 17K09789) and (B) (24390219 and 15H04900) and Grant-in-Aid for Scientific Research on Innovative Areas (Brain Protein Aging and Dementia Control) (26117003) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan and Novartis Research Grants. Publisher Copyright: Copyright © 2021 Ezura, Kikuchi, Okamura, Ishiki, Hasegawa, Harada, Watanuki, Funaki, Hiraoka, Baba, Sugeno, Yoshida, Kobayashi, Kobayashi, Tano, Ishiyama, Nakamura, Nakashima, Mugikura, Iwata, Taki, Furukawa, Arai, Furumoto, Tashiro, Yanai, Kudo, Takeda and Aoki.

PY - 2021/11/29

Y1 - 2021/11/29

N2 - Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer’s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: 18F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke’s Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson’s Disease Rating Scale Motor Score, and PSP Rating Scale. Results: 18F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. 18F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, 18F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional 18F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using 18F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.

AB - Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer’s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: 18F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke’s Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson’s Disease Rating Scale Motor Score, and PSP Rating Scale. Results: 18F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. 18F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, 18F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional 18F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using 18F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.

KW - Alzheimer’s disease (AD)

KW - F-THK5351

KW - corticobasal syndrome (CBS)

KW - monoamine oxidase B (MAO-B)

KW - positron emission tomography (PET)

KW - progressive supranuclear palsy (PSP)

KW - tau deposits

KW - tauopathy

UR - http://www.scopus.com/inward/record.url?scp=85121385073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121385073&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2021.761010

DO - 10.3389/fnagi.2021.761010

M3 - Article

AN - SCOPUS:85121385073

VL - 13

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

M1 - 761010

ER -